Investment Thesis
REGENEREX PHARMA is financially insolvent with negative stockholders equity of -4.7M, liabilities of 5.3M against only 617.8K in assets, and a critically depleted cash position of 11.7K. The company is burning nearly 1M in annual operating cash flow while generating virtually no revenue (1.8K), indicating complete operational failure and imminent solvency crisis.
Strengths
- Company still maintains legal entity status and SEC filing capability
- Debt load of 184.2K, while significant relative to assets, is not massive in absolute terms
- No material liabilities from failed clinical trials or major product recalls noted
Risks
- Negative stockholders equity of -4.7M indicates technical insolvency and bankruptcy risk
- Critical liquidity crisis with current ratio of 0.01x and only 11.7K cash against 5.3M liabilities
- Revenue has collapsed 31.9% YoY to negligible 1.8K, indicating no active commercial products or operations
- Severe cash burn of 997.3K annually with minimal cash reserves suggests runway of days, not months
- Zero insider trading activity suggests management lacks confidence in company viability
- Deeply negative margins across all metrics with operating losses of 1.4M on near-zero revenue
Key Metrics to Watch
- Stockholders equity trend - if becomes more negative, insolvency accelerates
- Cash balance - runway until complete depletion at current burn rate
- Revenue - any commercial traction would indicate operational restart
Financial Metrics
Revenue
1.8K
Net Income
-1.5M
EPS (Diluted)
$0.00
Free Cash Flow
-997.3K
Total Assets
617.8K
Cash
11.7K
Profitability Ratios
Gross Margin
-13,798.1%
Operating Margin
-80,027.8%
Net Margin
-83,244.8%
ROE
N/A
ROA
-239.2%
FCF Margin
-56,185.8%
Balance Sheet & Liquidity
Current Ratio
0.01x
Quick Ratio
-0.04x
Debt/Equity
N/A
Debt/Assets
860.6%
Interest Coverage
-30.67x
Long-term Debt
184.2K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-09T05:40:20.467276 |
Data as of: 2025-09-30 |
Powered by Claude AI